By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Data detailed on Eye Diseases and Conditions - Ocular Hypertension have been presented. According to news reporting out of Milan, Italy, by NewsRx editors, research stated, “In patients with ocular hypertension or glaucoma all treatments aim at lowering intraocular pressure (IOP) by modulating aqueous humor (AH) production and/or uveoscleral and trabecular meshwork /Schlemm’s canal AH drainage. Prostaglandin (PG) analogues are considered the ‘gold standard’, and are the most frequently used IOP-lowering agents.”

Our news journalists obtained a quote from the research from Nicox Research Institute, “Recent data support an important role of nitric oxide (NO) in regulating IOP. Thus novel PG analogues carrying a NO-donating moiety were recently advanced. Latanoprostene bunod (LBN) and NCX 470, respectively a NO-donating derivative of latanoprost and bimatoprost, are examples of such compounds. LBN ophthalmic solution, 0.024% (Vyzulta ) showed greater IOP-lowering efficacy compared with Xalatan? (latanoprost ophthalmic solution, 0.005%) or 0.5% timolol maleate in clinical settings. NCX 470 was found more effective than bimatoprost in animal models of ocular hypertension and glaucoma.”

According to the news editors, the research concluded: “Selective EP receptor agonists (i.e., taprenepag isopropyl, omidenepag isopropyl; aganepag isopropyl) and non-selective prostanoid receptors agonists (i.e., ONO-9054, sepetaprost isopropyl) that concomitantly stimulate FP and EP receptors also hold promise.”

For more information on this research see: Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. British Journal of Pharmacology , 2018;():. British Journal of Pharmacology can be contacted at: Nature Publishing Group, 345 Park Avenue South, New York, NY 10010-1707, USA. (Wiley-Blackwell - http://www.wiley.com/; British Journal of Pharmacology - http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381)

Our news journalists report that additional information may be obtained by contacting F. Impagnatiello, Nicox Research Institute, Milan, Italy. Additional authors for this research include E. Bastia, N. Almirante, S. Brambilla, B. Duquesroix, A.C. Kothe and M.VW Bergamini.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1111/bph.14328. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the British Journal of Pharmacology is: Nature Publishing Group, 345 Park Avenue South, New York, NY 10010-1707, USA.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

CITATION: (2018-05-06), Studies from Nicox Research Institute Yield New Information about Ocular Hypertension (Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma), Medical Devices & Surgical Technology Week, 1048, ISSN: 1537-1417, BUTTER® ID: 015572379

From the newsletter Medical Devices & Surgical Technology Week.
https://www.newsrx.com/Butter/#!Search:a=15572379

This is a NewsRx^® article created by NewsRx^® and posted by NewsRx^®. As proof that we are NewsRx^® posting NewsRx^® content, we have added a link to this steemit page on our main corporate website. The link is at the bottom left under "site links" at https://www.newsrx.com/NewsRxCorp/.

We have been in business for more than 20 years and our full contact information is available on our main corporate website.

We only upvote our posts after at least one other user has upvoted the article to increase the curation awards of upvoters.

NewsRx^® offers 195 weekly newsletters providing comprehensive information on all professional topics, ranging from health, pharma and life science to business, tech, energy, law, and finance. Our newsletters report only the most relevant and authoritative information from qualified sources.

View Newsletter Titles

About NewsRx^® and Contact Information

Topics